{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:22:34Z","timestamp":1785522154441,"version":"3.56.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Dis Travel Med Vaccines"],"DOI":"10.1186\/s40794-026-00302-6","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:45:02Z","timestamp":1779533102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Traveling with HIV"],"prefix":"10.1186","volume":"12","author":[{"given":"Victor Daniel","family":"Miron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rabbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Keertana","family":"Devarapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Fidji","family":"Glar\u00eda Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESCMID Study Group for Viral Hepatitis (ESGVH)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Daniel","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rabbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESCMID Sexually Transmitted Infections Study Group (ESTISG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Daniel","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Rabbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"302_CR1","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva: WHO; 2022."},{"issue":"8","key":"302_CR2","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"Antiretroviral Therapy Cohort C","year":"2017","unstructured":"Antiretroviral Therapy Cohort C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349\u201356.","journal-title":"Lancet HIV"},{"key":"302_CR3","unstructured":"European AIDS Clinical Society. EACS Guidelines version 13.0. October 2025. Available at: https:\/\/eacs.sanfordguide.com\/."},{"key":"302_CR4","unstructured":"UNAIDS. HIV-related travel restrictions. Accessed on 14. January 2026. Available at: https:\/\/travelrestrictions.unaids.org\/."},{"key":"302_CR5","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.lanepe.2020.100001","volume":"1","author":"MP Grobusch","year":"2020","unstructured":"Grobusch MP, Weld L, Goorhuis A, Hamer DH, Schunk M, Jordan S, et al. Travel-related infections presenting in Europe: a 20-year analysis of EuroTravNet surveillance data. Lancet Reg Health Eur. 2020;1:100001.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"302_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1473-3099(14)71000-X","volume":"15","author":"P Schlagenhauf","year":"2015","unstructured":"Schlagenhauf P, Weld L, Goorhuis A, Gautret P, Weber R, von Sonnenburg F, et al. Travel-associated infection presenting in Europe (2008-12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infect Dis. 2015;15(1):55\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"302_CR7","doi-asserted-by":"publisher","first-page":"e842","DOI":"10.1016\/j.ijid.2010.02.2251","volume":"14","author":"R Vivancos","year":"2010","unstructured":"Vivancos R, Abubakar I, Hunter PR. Foreign travel, casual sex, and sexually transmitted infections: systematic review and meta-analysis. Int J Infect Dis. 2010;14(10):e842\u201351.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"302_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/QCO.0000000000000513","volume":"32","author":"KE Rogstad","year":"2019","unstructured":"Rogstad KE. Sexually transmitted infections and travel. Curr Opin Infect Dis. 2019;32(1):56\u201362.","journal-title":"Curr Opin Infect Dis"},{"issue":"27","key":"302_CR9","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"302_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"key":"302_CR11","unstructured":"Positive Destinations. Information and advocacy on travelling and relocating with HIV. Accessed on 14. January 2026. Available at: https:\/\/www.positivedestinations.info\/."},{"key":"302_CR12","unstructured":"HIV Justice Network. Global HIV criminalisation database. Accessed on 14. January 2026. Available at: https:\/\/www.hivjustice.net\/global-hiv-criminalisation-database\/."},{"issue":"2","key":"302_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000458761","volume":"30","author":"S Goetze","year":"2017","unstructured":"Goetze S, Hiernickel C, Elsner P. Phototoxicity of Doxycycline: A Systematic Review on Clinical Manifestations, Frequency, Cofactors, and Prevention. Skin Pharmacol Physiol. 2017;30(2):76\u201380.","journal-title":"Skin Pharmacol Physiol"},{"issue":"1","key":"302_CR14","first-page":"57","volume":"79","author":"JD Kowalska","year":"2025","unstructured":"Kowalska JD, Zdolinska-Malinowska I, Siewaszewicz E, Mierzejewski P, Gmizic I, Ankiersztejn-Bartczak M. Telemedicine in HIV care in times of COVID-19 pandemic: a patient satisfaction survey study. Przegl Epidemiol. 2025;79(1):57\u201366.","journal-title":"Przegl Epidemiol"},{"issue":"8","key":"302_CR15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1086\/586713","volume":"197","author":"G Study","year":"2008","unstructured":"Strategies for Management of Antiretroviral Therapy, Study G, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133\u201344.","journal-title":"J Infect Dis"},{"key":"302_CR16","unstructured":"World Health Organization. Guidance on handling interruptions in antiretroviral treatment due to HIV service disruptions, drug shortages, or stockouts. Accessed on 14. January 2026. Available at: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/guidance-on-handling-interruptions-in-antiretroviral-treatment-due-to-hiv-service-disruptions--drug-shortages--or-stockouts."},{"issue":"12","key":"302_CR17","doi-asserted-by":"publisher","first-page":"102950","DOI":"10.1016\/j.jiph.2025.102950","volume":"18","author":"JD Kowalska","year":"2025","unstructured":"Kowalska JD, Matlosz B, Samsonova O, Antoniak S, Bienkowski C, Bursa D, et al. Continuity of HIV and hepatitis C care in times of war - Five Times Ninety project. J Infect Public Health. 2025;18(12):102950.","journal-title":"J Infect Public Health"},{"issue":"4","key":"302_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.pop.2011.07.005","volume":"38","author":"SM Shepherd","year":"2011","unstructured":"Shepherd SM, Shoff WH. Immunization in travel medicine. Prim Care. 2011;38(4):643\u201379. viii.","journal-title":"Prim Care"},{"key":"302_CR19","unstructured":"Bonnaci RA, Halsey ES. Travelers with HIV. In: CDC Yellow Book: Health Information for International Travel. 2026 ed. Available at: https:\/\/www.cdc.gov\/yellow-book\/hcp\/travelers-with-additional-considerations\/travelers-with-hiv.html."},{"key":"302_CR20","unstructured":"British HIV Association. BHIVA guidelines on the use of vaccines in HIV-positive adults 2015. Accessed on 20 2025. Available at: https:\/\/bhiva.org\/wp-content\/uploads\/2024\/10\/2015-Vaccination-Guidelines.pdf. Accessed 2025 Dec 20."},{"key":"302_CR21","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.tmaid.2025.102871","volume":"67","author":"AJ Rodriguez-Morales","year":"2025","unstructured":"Rodriguez-Morales AJ, Alhazmi AH, Katime A, Hameed AA, Morales A, Lepetic AC, et al. Yellow fever in South America - A plea for action and call for prevention also in travelers from SLAMVI, ESGITM, EVASG, ALEIMC, GEPI-SEIMC, SEMEVI, and CMTZMV-ACIN. Travel Med Infect Dis. 2025;67:102871.","journal-title":"Travel Med Infect Dis"},{"key":"302_CR22","unstructured":"Kroger AT, Duchin J, V\u00e1zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). [cited 2025 Dec 20]. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf."},{"issue":"2","key":"302_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7102a1","volume":"71","author":"JP Collins","year":"2022","unstructured":"Collins JP, Ryan ET, Wong KK, Daley MF, Ratner AJ, Appiah GD, et al. Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022. MMWR Recomm Rep. 2022;71(2):1\u20138.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"302_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/infdis\/jiv108","volume":"212","author":"LC Ivers","year":"2015","unstructured":"Ivers LC, Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, et al. Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection. J Infect Dis. 2015;212(5):779\u201383.","journal-title":"J Infect Dis"},{"issue":"50","key":"302_CR25","doi-asserted-by":"publisher","first-page":"7573","DOI":"10.1016\/j.vaccine.2023.10.055","volume":"41","author":"E Man-Lik Choi","year":"2023","unstructured":"Man-Lik Choi E, Abu-Baker Mustapher G, Omosa-Manyonyi G, Foster J, Anywaine Z, Musila Mutua M, et al. Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda. Vaccine. 2023;41(50):7573\u201380.","journal-title":"Vaccine"},{"issue":"3","key":"302_CR26","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1473-3099(24)00673-X","volume":"25","author":"A Rojek","year":"2025","unstructured":"Rojek A, Fieggen J, Apiyo P, Caluwaerts S, Fowler RA, Kaleebu P, et al. Ebola disease: bridging scientific discoveries and clinical application. Lancet Infect Dis. 2025;25(3):e165\u201376.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"302_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","volume":"68","author":"SL Hills","year":"2019","unstructured":"Hills SL, Walter EB, Atmar RL, Fischer M, Group AJEVW. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2019;68(2):1\u201333.","journal-title":"MMWR Recomm Rep"},{"key":"302_CR28","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1017\/S0950268821000194","volume":"149","author":"D Jilich","year":"2021","unstructured":"Jilich D, Maly M, Kosina P, Fleischhans L, Machala L. Immunogenicity and safety of rapid scheme vaccination against tick-borne encephalitis in HIV-1 infected persons. Epidemiol Infect. 2021;149:e41.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"302_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s15010-002-2020-6","volume":"31","author":"B Panasiuk","year":"2003","unstructured":"Panasiuk B, Prokopowicz D, Panasiuk A. Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection. 2003;31(1):45\u20136.","journal-title":"Infection"},{"issue":"10487","key":"302_CR30","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","volume":"405","author":"JS Richardson","year":"2025","unstructured":"Richardson JS, Anderson DM, Mendy J, Tindale LC, Muhammad S, Loreth T, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10487):1343\u201352.","journal-title":"Lancet"},{"issue":"10487","key":"302_CR31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","volume":"405","author":"LC Tindale","year":"2025","unstructured":"Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10487):1353\u201361.","journal-title":"Lancet"},{"key":"302_CR32","unstructured":"Panel on Guidelines for the Prevention. and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America. Accesed on 23 December 2025. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection."},{"issue":"1","key":"302_CR33","doi-asserted-by":"publisher","first-page":"16655","DOI":"10.1038\/s41598-021-95591-6","volume":"11","author":"A Mahittikorn","year":"2021","unstructured":"Mahittikorn A, Kotepui KU, De Jesus Milanez G, Masangkay FR, Kotepui M. A meta-analysis on the prevalence and characteristics of severe malaria in patients with Plasmodium spp. and HIV co-infection. Sci Rep. 2021;11(1):16655.","journal-title":"Sci Rep"},{"issue":"4","key":"302_CR34","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S2352-3018(24)00035-3","volume":"11","author":"A Figueroa-Romero","year":"2024","unstructured":"Figueroa-Romero A, Saura-Lazaro A, Fernandez-Luis S, Gonzalez R. Uncovering HIV and malaria interactions: the latest evidence and knowledge gaps. Lancet HIV. 2024;11(4):e255\u201367.","journal-title":"Lancet HIV"},{"issue":"1","key":"302_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa011699","volume":"347","author":"MS Fradin","year":"2002","unstructured":"Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med. 2002;347(1):13\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"302_CR36","doi-asserted-by":"publisher","first-page":"e3326","DOI":"10.1371\/journal.pntd.0003326","volume":"8","author":"K Van Roey","year":"2014","unstructured":"Van Roey K, Sokny M, Denis L, Van den Broeck N, Heng S, Siv S, et al. Field evaluation of picaridin repellents reveals differences in repellent sensitivity between Southeast Asian vectors of malaria and arboviruses. PLoS Negl Trop Dis. 2014;8(12):e3326.","journal-title":"PLoS Negl Trop Dis"},{"key":"302_CR37","volume-title":"Guidelines for malaria prevention in travellers from the United Kingdom, 2024","author":"PL Chiodini","year":"2024","unstructured":"Chiodini PL, Patel D, Goodyer L, Frise C, Mabayoje D, Aggarwal D. Guidelines for malaria prevention in travellers from the United Kingdom, 2024. London: UK Health Security Agency; October; 2024."},{"issue":"7","key":"302_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1473-3099(11)70031-7","volume":"11","author":"C Flateau","year":"2011","unstructured":"Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis. 2011;11(7):541\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"17","key":"302_CR39","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1001\/archinte.167.17.1827","volume":"167","author":"PE Brentlinger","year":"2007","unstructured":"Brentlinger PE, Behrens CB, Kublin JG. Challenges in the prevention, diagnosis, and treatment of malaria in human immunodeficiency virus infected adults in sub-Saharan Africa. Arch Intern Med. 2007;167(17):1827\u201336.","journal-title":"Arch Intern Med"},{"key":"302_CR40","unstructured":"Liverpool HIV drug interactions checker. Accessed on 14. January 2026. Available at: https:\/\/www.hiv-druginteractions.org\/checker."},{"key":"302_CR41","unstructured":"Ridpath AD, Wallender E, Malaria. In CDC Yellow Book: Health Information for International Travel. 2026 ed. Available at: https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/malaria.html."},{"issue":"10","key":"302_CR42","first-page":"CD006491","volume":"10","author":"M Tickell-Painter","year":"2017","unstructured":"Tickell-Painter M, Maayan N, Saunders R, Pace C, Sinclair D. Mefloquine for preventing malaria during travel to endemic areas. Cochrane Database Syst Rev. 2017;10(10):CD006491.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"302_CR43","doi-asserted-by":"publisher","first-page":"e0173509","DOI":"10.1371\/journal.pone.0173509","volume":"12","author":"K Seden","year":"2017","unstructured":"Seden K, Gibbons S, Marzolini C, Schapiro JM, Burger DM, Back DJ, et al. Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLoS ONE. 2017;12(3):e0173509.","journal-title":"PLoS ONE"},{"issue":"9","key":"302_CR44","first-page":"CD006689","volume":"9","author":"C Pons-Duran","year":"2024","unstructured":"Pons-Duran C, Wassenaar MJ, Yovo KE, Marin-Carballo C, Briand V, Gonzalez R. Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women. Cochrane Database Syst Rev. 2024;9(9):CD006689.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10424","key":"302_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(23)02631-4","volume":"403","author":"HC Barsosio","year":"2024","unstructured":"Barsosio HC, Madanitsa M, Ondieki ED, Dodd J, Onyango ED, Otieno K, et al. Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial. Lancet. 2024;403(10424):365\u201378.","journal-title":"Lancet"},{"issue":"6","key":"302_CR46","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4103\/ijmr.IJMR_1167_19","volume":"154","author":"J Sharma","year":"2021","unstructured":"Sharma J, Gautam CS, Singh H, Singh J. Tafenoquine for Plasmodium vivax malaria: Concerns regarding efficacy & safety. Indian J Med Res. 2021;154(6):797\u2013805.","journal-title":"Indian J Med Res"},{"issue":"10","key":"302_CR47","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1473-3099(24)00236-6","volume":"24","author":"JM Molina","year":"2024","unstructured":"Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design. Lancet Infect Dis. 2024;24(10):1093\u2013104.","journal-title":"Lancet Infect Dis"},{"key":"302_CR48","doi-asserted-by":"crossref","unstructured":"Raskin RB, O\u2019Neal IR, de Pina G, Palafox E, Suprasert B, Ruiz R, et al. Doxycycline post-exposure prophylaxis awareness and use among transgender women in San Francisco, 2023\u20132024: assessment one year after release of health department guidance. AIDS Behav. 2025.","DOI":"10.1007\/s10461-025-04912-7"},{"issue":"8","key":"302_CR49","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(25)00085-4","volume":"25","author":"AF Luetkemeyer","year":"2025","unstructured":"Luetkemeyer AF, Donnell D, Cohen SE, Dombrowski JC, Grabow C, Haser G, et al. Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension. Lancet Infect Dis. 2025;25(8):873\u201383.","journal-title":"Lancet Infect Dis"},{"key":"302_CR50","volume-title":"Public health considerations on the use of doxycycline for post-exposure prophylaxis for bacterial sexually transmitted infections in the EU\/EEA","author":"European Centre for Disease Prevention and Control","year":"2026","unstructured":"European Centre for Disease Prevention and Control. Public health considerations on the use of doxycycline for post-exposure prophylaxis for bacterial sexually transmitted infections in the EU\/EEA. Stockholm: ECDC; 2026."},{"key":"302_CR51","first-page":"101663","volume":"61","author":"I Maatouk","year":"2025","unstructured":"Maatouk I, Vumbugwa P, Cherdtrakulkiat T, Heng LS, Hoffman I, Palaypayon N, et al. Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study. Lancet Reg Health West Pac. 2025;61:101663.","journal-title":"Lancet Reg Health West Pac"},{"key":"302_CR52","unstructured":"Mohseni M, Sung S, Rausch-Phung EA, et al. Chlamydia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan [updated 2025 Dec 13] Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537286\/."},{"issue":"6","key":"302_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/09564624251323678","volume":"36","author":"JA White","year":"2025","unstructured":"White JA, Dukers-Muijrers NH, Hoebe CJ, Kenyon CR, Dc Ross J, Unemo M. 2025 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS. 2025;36(6):434\u201349.","journal-title":"Int J STD AIDS"},{"issue":"3","key":"302_CR54","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/jdv.16946","volume":"35","author":"M Janier","year":"2021","unstructured":"Janier M, Unemo M, Dupin N, Tiplica GS, Potocnik M, Patel R. 2020 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2021;35(3):574\u201388.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"302_CR55","doi-asserted-by":"crossref","unstructured":"Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions. Antimicrob Agents Chemother. 2020;64(3).","DOI":"10.1128\/AAC.02167-19"},{"issue":"1","key":"302_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/QCO.0000000000001171","volume":"39","author":"G Monsel","year":"2026","unstructured":"Monsel G, Jabet A. Sexually transmitted dermatophytosis - what do we know about epidemiology, transmission, and treatment of this emerging class of STI? Curr Opin Infect Dis. 2026;39(1):51\u201360.","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"302_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.35772\/ghm.2023.01064","volume":"5","author":"A Kawashima","year":"2023","unstructured":"Kawashima A, Yanagawa Y, Shimogawara R, Yagita K, Gatanaga H, Watanabe K. Amebiasis as a sexually transmitted infection: A re-emerging health problem in developed countries. Glob Health Med. 2023;5(6):319\u201327.","journal-title":"Glob Health Med"},{"issue":"4","key":"302_CR58","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/jdv.19664","volume":"38","author":"C Chessell","year":"2024","unstructured":"Chessell C, Rabuszko L, Richardson D, Llewellyn C. Factors associated with the sexual transmission of Strongyloides stercoralis in men who have sex with men: A systematic review. J Eur Acad Dermatol Venereol. 2024;38(4):673\u20139.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Tropical Diseases, Travel Medicine and Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40794-026-00302-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-026-00302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-026-00302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:12:19Z","timestamp":1785517939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40794-026-00302-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1186\/s40794-026-00302-6","relation":{},"ISSN":["2055-0936"],"issn-type":[{"value":"2055-0936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and consent to participate was not needed.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not needed.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26"}}